Neutrophil-to-eosinophil ratio predicts the efficacy of avelumab in patients with advanced Urothelial Carcinoma enrolled in the MALVA study (Meet-URO 25).

Neutrophil-to-eosinophil ratio predicts the efficacy of avelumab in patients with advanced Urothelial Carcinoma enrolled in the MALVA study (Meet-URO 25).

Autore

Elisabetta Gambale

Patologia

Urotelio

Rivista

Clinical Genitourinary Cancer

Anno

2024

DOI

https://doi.org/10.1016/j.clgc.2024.102099

Studio di riferimento

Meet-URO 25